Cargando…
Advances in Cancer Signal Transduction and Therapy /
Cancer is driven by numerous genetic and epigenetic changes occurring at the cellular level. These changes drive normal cells to proliferate and escape processes that usually regulate their survival and migration. Many of these alterations are often associated with signaling pathways which regulate...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Singapore :
Bentham Science Publishers,
2020.
|
| Colección: | Recent advances in signal transduction research and therapy ;
v. 1. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | EBSCO_on1206395838 | ||
| 003 | OCoLC | ||
| 005 | 20231017213018.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 201114s2020 si o 000 0 eng d | ||
| 040 | |a EBLCP |b eng |c EBLCP |d YDX |d N$T |d OCLCO |d EBLCP |d UKAHL |d OCLCF |d OCLCO |d OCLCQ |d OCLCO | ||
| 019 | |a 1200197276 | ||
| 020 | |a 9789811458118 |q (electronic bk.) | ||
| 020 | |a 9811458111 | ||
| 020 | |z 9789811458095 | ||
| 035 | |a (OCoLC)1206395838 |z (OCoLC)1200197276 | ||
| 050 | 4 | |a RC270.8 | |
| 082 | 0 | 4 | |a 571.7/4 |2 23 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Advances in Cancer Signal Transduction and Therapy / |c editors, Manoj K. Pandey, Vijay P. Kale. |
| 260 | |a Singapore : |b Bentham Science Publishers, |c 2020. | ||
| 300 | |a 1 online resource (207 p.). | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Recent Advances in Signal Transduction Research and Therapy ; |v volume 1 | |
| 520 | |a Cancer is driven by numerous genetic and epigenetic changes occurring at the cellular level. These changes drive normal cells to proliferate and escape processes that usually regulate their survival and migration. Many of these alterations are often associated with signaling pathways which regulate cell growth and division, cell death, survival, invasion and metastasis, and angiogenesis. Almost all cancer cells show high expression of signaling components including growth factor receptor tyrosine kinases (RTKs), small GTPases, serine/threonine kinases, cytoplasmic tyrosine kinases, lipid kinases, estrogen receptor, activation of transcription factors Myc and NF-Îo.B, etc. Updated knowledge about these signaling components is highly desirable for researchers involved in developing therapies against cancer. Signal Transduction Research for Cancer Therapy covers advancements in research on the signaling pathways in the human body, especially in some types of cancers, such as breast cancer, pancreatic cancer and colon cancer. Key features of this volume include 8 focused topical reviews on signaling pathways in a specific cancer type, coverage of multiple cancer types (breast cancer, colon cancer, hepatocellular cancer, multiple myeloma, acute myeloid leukemia, and pancreatic cancer), and coverage of a wide array of signaling pathways (both receptor mediated and non receptor mediated pathways). This volume is essential reading for researchers in pharmaceutical R&D and postgraduate research programs in pharmacology and allied disciplines. Clinicians involved in oncology will also benefit from the information provided in the chapters. | ||
| 505 | 0 | |a Cover -- Title -- Copyright -- End User License Agreement -- CONTENTS -- PREFACE -- List of Contributors -- Wnt Signaling in Breast Cancer Oncogenesis, Development and Progression -- Norman Fultang and Bela Peethambaran* -- INTRODUCTION -- Overview -- Wnt Biosynthesis and Regulation -- TYPES OF PATHWAYS -- The Canonical Wnt Signaling Pathway in Breast Cancer -- Non-canonical Wnt Pathways in Breast Cancer -- Regulators of Wnt Signaling -- Wnt and Breast Cancer Stem Cells -- ROLE OF WNT SIGNALING IN BREAST CANCER TUMORIGENESIS AND PROGRESSION | |
| 505 | 8 | |a 4. ANIMAL MODELS AND CLINICAL SIGNIFICANCE OF WNT SIGNALING IN BREAST CANCER -- 5. WNT SIGNALING IN TRIPLE-NEGATIVE BREAST CANCER -- NATURAL COMPOUNDS TARGETING WNT PATHWAYS AS CANCER THERAPEUTICS -- SMALL MOLECULES AND NOVEL THERAPEUTICS THAT TARGET WNT SIGNALING -- CONCLUSION AND FUTURE DIRECTIONS -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- CXCR4 Signaling and its Impact on Tumor Progression and Metastasis in Breast Cancer -- Dayanidhi Raman*, Cory M. Howard, Sangita Sridharan and Augustus M.C. Tilley -- INTRODUCTION | |
| 505 | 8 | |a CXCL12-CXCR4 AXIS -- CXCR4 PATHWAYS OPERATING IN BREAST CANCER -- PI3K Pathway -- AKT (or Protein Kinase B) Signaling Node -- mTOR Node -- MAPK Pathway -- Oncoprotein Translation by MAPKs -- Epithelial-mesenchymal Transition (EMT) and Cell Migration -- Inactivation of ERK1/2 -- C-SRC Pathway -- JAK-STAT Pathway -- Cross-talk of CXCR4 with Other Receptor and Non-receptor Tyrosine Kinases and its Interaction with Specific Adaptors -- Stromal Cell Recruitment to the TME -- Therapeutic Implications -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES | |
| 505 | 8 | |a Epidermal Growth Factor Receptor Signaling in Colon Cancer -- Avtar S. Meena1,* and Pradeep K. Shukla2,* -- COLORECTAL CANCER AND RISK FACTORS -- EGFR SIGNALING IN CRC -- EGF-like Growth Factors -- MAPK Signaling -- PI3K/ Akt Signaling -- Emerging Role of EGFR in the Development of Colon Cancer -- EGFR THERAPIES -- Anti-EGFR Receptor Therapy -- Anti-EGFR Monoclonal Antibodies -- Cetuximab -- Panitumumab -- Anti-EGFR Tyrosine Kinase Inhibitors -- Erlotinib -- Gefitinib -- MECHANISM OF RESISTANCE TO ANTI-EGFR THERAPY -- Low Expression of Amphiregulin, Epiregulin, and EGFR Gene Copy Number | |
| 505 | 8 | |a EGFR Downstream Effectors -- RAS -- RAF -- PIK3CA -- PTEN -- ROLE OF EGFR IN OTHER DISEASE MODELS -- EGFR and Probiotics -- EGFR and Inflammation -- EGFR and Glutamine -- FUTURE DIRECTION -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Targeting the PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma: Current State and Future Trends -- Neelam Yadav* and Yoganchal Mishra1 -- INTRODUCTION -- Risk Factors for HCC -- Pathophysiology -- Basic Signaling Pathways -- PI3K/AKT/MTOR SIGNALING PATHWAY -- Activation of PI3K/Akt/mTOR Pathway | |
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 650 | 0 | |a Cellular signal transduction. | |
| 650 | 0 | |a Cancer |x Treatment |x Technological innovations. | |
| 650 | 0 | |a Tumor suppressor proteins |x Research. | |
| 650 | 0 | |a Cancer |x Chemotherapy. | |
| 650 | 2 | |a Signal Transduction | |
| 650 | 6 | |a Transduction du signal cellulaire. | |
| 650 | 6 | |a Protéines suppresseurs de tumeurs |x Recherche. | |
| 650 | 6 | |a Cancer |x Chimiothérapie. | |
| 650 | 7 | |a Cancer |x Chemotherapy |2 fast | |
| 650 | 7 | |a Cancer |x Treatment |x Technological innovations |2 fast | |
| 650 | 7 | |a Cellular signal transduction |2 fast | |
| 700 | 1 | |a Pandey, Manoj K. | |
| 700 | 1 | |a Kale, Vijay P. | |
| 776 | 0 | 8 | |i Print version: |a Pandey, Manoj K. |t Advances in Cancer Signal Transduction and Therapy |d Singapore : Bentham Science Publishers,c2020 |z 9789811458095 |
| 830 | 0 | |a Recent advances in signal transduction research and therapy ; |v v. 1. | |
| 856 | 4 | 0 | |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2649040 |z Texto completo |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH37877141 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL6388632 | ||
| 938 | |a YBP Library Services |b YANK |n 301624537 | ||
| 938 | |a EBSCOhost |b EBSC |n 2649040 | ||
| 994 | |a 92 |b IZTAP | ||